US Health Care Professional Perspectives on Adverse Drug Event Reporting in the Hospital Setting and the
Opportunity for Information Technology
Gustavo Grampp Amgen Inc.
!Stella Stergiopoulos, Tufts CSDD; Carrie A. Brown, Tufts University;
Thomas Felix, Amgen Inc.; Kenneth A. Getz; Tufts CSDD
Disclosure - !"#$%#&#'%("$)#&(%*+#)$*,$-"*&$.%#&#,-'/0,$1'&$&2..0%-#)$+3$'$4%',-$5%06$764#,$8,(9$-0$!2:&$;#,-#%$50%$-"#$<-2)3$05$=%24$=#>#?0.6#,-9$$8,-#%.%#-'/0,&$.%0>*)#)$%#.%#&#,-$-"#$&"'%#)$.#%&.#(/>#&$05$-"#$'2-"0%&9$
"!
What is the role of health information technology (HIT) in pharmacovigilance?
•! #$%&'(!)%*!+,!-!+-../,.!*%!.,0%.1)2!-(3,.4,!(.&2!,3,)*4!567849!•! #$%&'(!'/):!0-1,)*!;-.,<!0$-.=-;>!-)(!/)41*&1%)-'!4-?,*>!4>4*,=4!
•! @(,)1A-+',!0-1,)*<!.,0%.*-+',!,3,)*<!4&40,;*!(.&2!540%)*-),%&4!.,0%.*49!
•! #$%&'(!;%=0'>!B/*$!2%3,.)=,)*!0%'/;/,4!-)(!4*-)(-.(4!
•! C.%(&;*D40,;/A;!-)(!+-*;$D40,;/A;!*.-;:/)2!%?!+/%'%2/;-'!0.%(&;*4!
E!
Tufts CSDD 2014 Survey of ADE Reporting Practices in the US
F! @)*,.3/,B,(!GG!,H0,.*4!/)!=,(/;/),<!0$-.=-;>!-)(!/)(&4*.>!
F! I-00,(!678!.,0%.1)2!0.%;,44!J%B4!-)(!K@L!4>4*,=4!/)!$%40/*-'4<!;'/)/;4!-)(!0$-.=-;/,4!
C$-4,!G!
F! M.,-*,(!-)(!(/4*./+&*,(!4&.3,>!/)4*.&=,)*!*%!N#!0.-;11%),.4!/)!3-./%&4!4,O)24!5$%40/*-'<!0$-.=-;><!;'/)/;9!
F! P,;,/3,(!QR!.,40%)4,4!?.%=!$%40/*-'!0.-;11%),.4!50$-.=-;/4*4<!I74<!)&.4,49!
C$-4,!"!
S!
!"#$%&'()*+,--'.&*/'%"0'1%2'3"%&4-#-'
56%"$74#"8'9:,'(%)$,-'%"0';4-9,<-'#"=*&=,0'#"'3>?'@,2*)$"8'
C.-;1;,!.,'-*,(!A)(/)24!-.,!0.,4,)*,(!/)!(*-9,)'(ABC'-*!*$/4!;%)?,.,);,T!
Phase 1 findings related to HIT: Many systems are used in typical hospital practice
8',;*.%)/;!#>4*,=4!
8KPU8IP!
MCV8!
,I6P!
WMI6!
WMIC!
@P!
X!
?&,+9)*"#+';4-9,<-'
8KPU!8IP' 8',;*.%)/;!K,-'*$!P,;%.(4U8',;*.%)/;!I,(/;-'!P,;%.(4!
MCV8' M%=0&*,./Y,(!C$>4/;/-)!V.(,.!8)*.>!4>4*,=!
,I6P' 8',;*.%)/;!I,(/;-1%)!6(=/)/4*.-1%)!P,;%.(!
WMI6' W-.;%(,D,)-+',(!I,(/;-1%)!6(=/)/4*.-1%)!
WMIC' W-.DM%(,!I,(/;-1%)!C.,0-.-1%)!L,;$)%'%2/,4!@P' 8',;*.%)/;!/);/(,)*!.,0%.1)2!4>4*,=!
Phase 2: Survey findings identified a typical Hospital-based ADE reporting process flow
Z!
7.&2!#&40,;*,(!
7.&2!-)(!68!7%;&=,)*,(!/)!C-1,)*!P,;%.(4!
P,*./,3,!7,*-/'4!-+%&*!*$,!7.&2!
P,*./,3,!7,*-/'4!-+%&*!*$,!6(3,.4,!
83,)*!
P,0%.*!6(3,.4,!83,)*!
7.&2!-)(!68!7%;&=,)*,(!/)!@)*,.)-'!@);/(,)*!P,0%.*!
I%4*!.,40%)(,)*4!$-3,!4&+=/[,(!/)*,.)-'!.,0%.*4!5RS\9<!+&*!=-)>!$-(!-'4%!.,0%.*,(!*%!]76!5XG\9!%.!-!=-)&?-;*&.,.!5EX\9^!
^!_&,41%)!B-4!`L%!B$/;$!%?!*$,!?%''%B/)2!%.2-)/Y-1%)4!$-3,!>%&!.,0%.*,(!-)!678a!54,',;*!-''!*$-*!-00'>9b!5)c!XR9!
R!
Phase 2 survey identified key factors preventing ADE reporting in Hospitals!"
D!E'),&%9,0'
@2#&/0,$'&A#)B$CD'&#)$0,$302%$#E.#%*#,(#F$"01$0:#,$)0$#'("$05$-"#&#$%#'&0,&$.%#>#,-$"#'?-"$('%#$.%0>*)#%&$5%06$%#.0%/,4$7=G&$-0$-"#$H=7$0%$-"#$6',25'(-2%#%IJ$5)!c!QR9!
Lack of system integration was cited as a significant reason for not reporting ADEs (52%)*
d,>!(,*-/'4!-.,!40.,-(!-=%)2!=&'10',!(-*-!4%&.;,4!
•!7.&2!(,*-/'4!40.,-(!-;.%44!S!%.!=%.,!4%&.;,4!5SZ\<!)cRS9!
•!678!(,*-/'4!40.,-(!-;.%44!E!%.!=%.,!4%&.;,4!5XG\<!)cZe9!!
Q!
>)68'0,9%#&-'' 3>?'0,9%#&-',I6P!5Ee\9' 8KP!U!8IP!5S"\9'
8KP!U!8IP!5EX\9' @P!#>4*,=!5Ef\9'MCV8!5"X\9'
V*$,.!)%)DK@L!4%&.;,4g!!!C$-.=-;>!5ER\9!!!C-1,)*!M$-.*!5"Q\9!!!C-0,.!+-4,(!@P!5G"\9$
V*$,.!)%)DK@L!4%&.;,4g!!!C-1,)*!;$-.*!5SS\9!!!M-.,!2/3,.!5"Q\9!!!C-0,.!+-4,(!@P!5GG\9$
@,2*)9,0'-*6)+,-'7*)'0,9%#&-''FG'*7'),-2*"0,"9-H'
^_&,41%)!B-4!!`W-4,(!%)!>%&.!,H0,./,);,<!$%B!%h,)!(%!,-;$!%?!*$,4,!.,-4%)4!0.,3,)*!$,-'*$!;-.,!0.%3/(,.4!?.%=!.,0%.1)2!6784!*%!*$,!]76!%.!*$,!=-)&?-;*&.,.a!`!5)cQR9!
Limited availability of important drug data elements in HIT systems
e!i%*,g!i!c!ZET!!_&,41%)!B-4!`j$/;$!%?!*$,!?%''%B/)2!(-*-!-+%&*!*$,!0-.1;&'-.!(.&2!-(=/)/4*,.,(!*%!-!0-.1;&'-.!0-1,)*!-.,!.%&1),'>!-3-/'-+',!/)!>%&.!,',;*.%)/;!4>4*,=4ab!
•! I-)&?-;*&.,.!5A,'(!%.!i7M!;%(,9!-)(!'%*!/(,)1A,.4!-.,!4;-.;,!/)!=%4*!4>4*,=4!•! W-.!;%(,!+-4,(!4>4*,=4!=->!/=0.%3,!(-*-!;-0*&.,!
IJE?K'I>L'/#&&'M,'6-,0'%-'9:,'N;'2)*06+9'#0,"$O,)'#"''9:,'!;J'!>P('
Could HIT impact drug identification in other countries? #$%&!'()*+,!-.!/0123'4!4-'03516'!'4-7+8!5415!'-9+!+:0)+';)3<32=!','5+9'!+2;-()1=+!-)!)+>(3)+!?@@!0)+';)3<32="
Gf!
6.,!4&;$!4>4*,=4!;%=0-1+',!B/*$!*$,!8M!Ck!(/.,;13,a!`!"#!$#%%$#&&'(&')#!*$+*#,-'*,$#'*$!#.*/$!($)0*/123$4%*#'%3$#/3$5)(%(6)4#%$+*0)4)/#%$&'(0-4!$&'*,4')5*07$8)!"$0-*$'*6#'0$!($!"*$/#+*$(2$!"*$+*0)4)/#%$&'(0-4!bG!!
G!M%&);/'!7/.,;13,!"fGfUQSU8M<!-.*T!Gf"5,9<!"fGf!VTlT!5m!ESQ9!RS<!QS!5-=,)(/)2!M%&);/'!7/.,;13,!"ffGUQSU8M9T!
!!
='-'$(02%-#&3$05$H'%6'*,)2&-%*'$E*9%&'M,0-K'QRSTUV'
Can the medicines be looked for by brand?
Is INN only predefined in a drop down menu so that the doctor can select it?
Summary and Discussion
•! K%40/*-'!@L!4>4*,=4!-.,!-)!,44,)1-'!4%&.;,!?%.!.,;%.(/)2!-)(!.,*./,3/)2!678!-)(!4&40,;*!(.&2!/)?%.=-1%)!
•! C.,4,);,!%?!=&'10',!4>4*,=4!*$-*!'-;:!/)*,2.-1%)!=->!+,!-)!%+4*-;',!*%!,n;/,)*!678!.,0%.1)2!
•!I-)>!4>4*,=4!=->!)%*!;-0*&.,!(.&2!/(,)1A,.4!%*$,.!*$-)!+.-)(!-)(U%.!@ii!
•! P,;%==,)(-1%)4g!•! @=0.%3,!-;;,44!*%!/)?%.=-1%)g!!@)*,.%0,.-+/'/*>U/)*,2.-1%)!%?!(.&2!/(,)1A,.4!-)(!678!(-*-!?.%=!=&'10',!4>4*,=4!
•! #>4*,=!(,4/2)4!4$%&'(!0,.=/*!&4,!%?!+.-)(!)-=,4!?%.!+/%'%2/;4!•! @)*,2.-*,!0.%(&;*D40,;/A;!(-*-!?.%=!+-.!;%(,!+-4,(!4>4*,=4!/)*%!%*$,.!K@L!4>4*,=4!*%!/=0.%3,!'%*D',3,'!*.-;,-+/'/*>!
GG!
Limitations
•! L$,!=-o%./*>!%?!$%40/*-'!+-4,(!4&.3,>!.,40%)4,4!%./2/)-*,(!?.%=!E!N#!4*-*,4!5i,B!p%.:<!i,B!l,.4,><!j-4$/)2*%)9!
•! "E\!%?!$%40/*-'!.,40%)(,)*4!5)cX"9!$-(!),3,.!.,0%.*,(!-)!678!5/)*,.)-''>!%.!,H*,.)-''>9!
•! SQ\!$-(!),3,.!.,0%.*,(!-)!678!*%!]76!%.!-!=-)&?-;*&.,.!
G"!
Thank you! q&4*-3%!q.-=00!
6=2,)!@);T!
About the Tufts CSDD
•! M,)*,.!-*!L&h4!N)/3,.4/*>!#;$%%'!%?!I,(/;/),!5$[0gUU;4((T*&h4T,(&9!
•! @)(,0,)(,)*<!-;-(,=/;!2.%&0!?%;&4/)2!%)!(.&2!(,3,'%0=,)*!4;/,)1A;<!.,2&'-*%.><!,;%)%=/;!-)(!=-)-2,=,)*!0%'/;>!
•! q.-)*!?&)(,(!-)(!5;.%44D/)(&4*.>9!40%)4%.,(!4*&(/,4!!
•! P,4&'*4!$-3,!/)?%.=,(!M%)2.,44<!*$,!i-1%)-'!6;-(,=/,4!%?!#;/,);,<!]%&)(-1%)4<!@)(&4*.><!M-0/*-'!I-.:,*!-)-'>4*4!-)(!/)3,4*%.4<!P,2&'-*%.>!62,);/,4<!*$,!i-1%)-'!@)41*&*,4!%?!K,-'*$!
GS!
Tufts CSDD: Furthering the Cause of Pharmaceutical Innovation
!!!!!!
Staff Presentations
Louis Lasagna Library of Drug Development
Electronic Databases &
Bibliographies
!!Sponsorship
!!!
Surveys & Questionnaires
Information Services
Multi-Company Project Series
!!
Manuscripts, White Papers & Book Chapters
!
Research and Publications
!
Industry Programs
Sponsored Research Projects
!!!
Commentaries & Editorials
Tufts CSDD Executive
Forum !!
Public Hearings & Testimony
!
Tufts Center for the Study of Drug Development
Quarterly Updates
!!
Bi-Monthly Impact Report
T U F T S U N I V E R S I T Y !Annual
Postgraduate Course
!!!
Annual Outlook Report
!
Subscription- Based Reports
!
Training & Workshops
Annual Leadership
Course !!!
Quarterly R&D Mgmt. Report
!!
Webinars, Wkshps., & R&D
Roundtables